Business
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solve...
About this update from Prime Drink Group Corp
[{"type":"text","content":"\n\n\nThe $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCanada NewsWire\n\n\nIssued on behalf of Avaí Bio, Inc.USANewsGroup.comVANCOUVER, BC, March 31, 2026 /CNW/ -- The FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578 billion by 2033. Cell therapy alone surpassed $8.2 billion this year. And yet the central challenge of the entire sector remains unresolved: how do you manufacture living therapeutics at scale, consistently, and affordably?\n\n\n\n\n\n\n\nEvery cell therapy company confronts the same bottleneck. You can discover a transformative biological mechanism in a lab. You can prove it works in a trial. But the moment you need to produce it reliably for thousands or millions of patients, you run into the manufacturing wall. The cells degrade. The immune system rejects them. The supply chain breaks. The companies that solve manufacturing are the ones that will capture the value in this market.That manufacturing challenge is driving some of the most important milestones in the sector right now. Prime Medicine (NASDAQ: PRME) is developing prime editing — a next-generation gene editing platform that rewrites DNA without cutting both strands, reducing the off-target risks that have haunted earlier CRISPR approaches. The technology promises more precise manufacturing of gene-corrected cells at scale. Madrigal Pharmaceuticals (NASDAQ: MDGL) presented two-year data showing its therapy Rezdiffra significantly improved liver stiffness and fibrosis biomarkers in patients with compensated MASH cirrhosis, demonstrating that manufactured biologics can deliver sustained, measurable reversal of chronic organ damage.Iovance Biotherapeutics (NASDAQ: IOVA) received FDA approval for Amtagvi, a tumor-infiltrating lymphocyte therapy for advanced melanoma — the first approved TIL therapy, which requires extracting and expanding a patient's own immune cells in a centralized manufacturing f...